Cargando…

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy

Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. We evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navari, Rudolph M., Rapoport, Bernardo L., Powers, Dan, Arora, Sujata, Clark‐Snow, Rebecca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051205/ https://www.ncbi.nlm.nih.gov/pubmed/29790666 http://dx.doi.org/10.1002/cam4.1560

Ejemplares similares

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
por: Chasen, Martin, et al.
Publicado: (2016)

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
por: Hesketh, Paul J., et al.
Publicado: (2016)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
por: Rapoport, Bernardo Leon
Publicado: (2017)

Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
por: Rapoport, Bernardo Leon, et al.
Publicado: (2017)

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
por: Rashad, Noha, et al.
Publicado: (2017)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy
por: Navari, Rudolph M, et al.
Publicado: (2019)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
por: Weinstein, Cindy, et al.
Publicado: (2020)

Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
por: Park, Hyung Soon, et al.
Publicado: (2020)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
por: Yoshida, Naohisa, et al.
Publicado: (2019)

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
por: Hu, Zhihuang, et al.
Publicado: (2016)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)
por: Weinstein, C., et al.
Publicado: (2016)

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
por: Navari, Rudolph M, et al.
Publicado: (2023)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
por: Barbour, S., et al.
Publicado: (2017)

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
por: Willier, Semjon, et al.
Publicado: (2019)

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
por: Navari, Rudolph M.
Publicado: (2015)

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015)

Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study
por: Wu, Xuan, et al.
Publicado: (2020)

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
por: Boccia, Ralph, et al.
Publicado: (2016)

Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022)

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
por: Boccia, Ralph, et al.
Publicado: (2013)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
por: Lee, So Rae, et al.
Publicado: (2020)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
por: Chang, Jianhua, et al.
Publicado: (2020)

Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study
por: Kimura, Hiroaki, et al.
Publicado: (2015)

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
por: Celio, Luigi, et al.
Publicado: (2019)

Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
por: Sugawara, Shunichi, et al.
Publicado: (2019)

Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
por: van der Vorst, Maurice J.D.L., et al.
Publicado: (2020)

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)
por: Karthaus, Meinolf, et al.
Publicado: (2015)

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
por: Choi, Brian S., et al.
Publicado: (2014)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
por: Boccia, Ralph V., et al.
Publicado: (2010)

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
por: Kang, Jin Hyoung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e41g16c2vbuusn45londfg0epd